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In Vitro and In Vivo Characterization of a Fully Felinized
Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the
Treatment of Pain in Cats
D.P. Gearing, M. Huebner, E.R. Virtue, K. Knight, P. Hansen, B.D.X. Lascelles, R.P. Gearing, and
A.C. Drew
Background: Limited options are available for the treatment of pain in cats. Monoclonal antibodies (mAbs) that neutral-
ize nerve growth factor (NGF) have demonstrated analgesic capacity in rodent models, people with osteoarthritis, and dogs
with degenerative joint disease.
Hypothesis/Objectives: This study describes the design and characterization of a fully felinized anti-NGF monoclonal
antibody. In vitro potency, pharmacokinetics, and the ability of the antibody to treat pain in a self-resolving, acute inflamma-
tion model were investigated in cats.
Animals: Thirty-eight cats at a research colony at Charles River Laboratories, Ireland.
Methods: Felinized anti-NGF mAb, NV-02, was produced using a complementary DNA (cDNA)-based method (PETiza-
tion). Purified NV-02 was tested for affinity, potency, and immunoreactivity in vitro, then for safety and plasma pharmacoki-
netic distribution in vivo, and analgesic efficacy in a model of kaolin-induced inflammatory pain.
Results: Anti-NGF mAb, NV-02 neutralized NGF with high affinity and potency and did not bind complement. NV-02-
administered SC had a plasma half-life of 7–15 days and was well tolerated at dosages up to 28 mg/kg. A dosage of 2 mg/kg
NV-02 SC significantly decreased signs of lameness on day 2 (P = .0027), day 3 (P = .016), day 4, (P = .0063), day 5
(P = .0085), day 6 (P = .0014), and day 7 (P = .0034) after induction of inflammation.
Conclusions and Clinical Importance: The high affinity, long plasma half-life, safety, and analgesic efficacy of felinized
anti-NGF mAb (NV-02) support further investigation of the analgesic potential of this antibody in the cat.
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Nonsteroidal anti-inflammatory drugs (NSAIDs) areused commonly in other mammals for pain relief,
but are not widely used for control of pain in cats
because of safety concerns.1 In the United States, no
NSAIDs are approved for chronic use in cats, and in
the European Union (EU), only 1 NSAID (meloxicam)
is approved for the treatment of chronic pain. However,
in the United States, meloxicam has a boxed warning,
cautioning against repeated dosing.
Anti-nerve growth factor (NGF) monoclonal anti-
bodies (mAbs) have been shown to have analgesic
effects in rodent models of pain,2 in several human clin-
ical trials3–5 and, more recently, in proof-of-concept
clinical studies in osteoarthritic dogs.6–8 Long-acting
pain relief (>4 weeks) and good tolerability was
observed in the dog studies after a single injection.
Although no published data are available linking
NGF and pain in cats, the amino acid sequences of
human and feline NGF are highly conserved (Fig 1A).
Given the long half-life of mAbs in mammals in gen-
eral, the favorable safety of humanized antibodies as a
class, and the potential for an equivalent role of NGF
in mediating pain in cats, as in other mammals, we rea-
soned that a felinized mAb (ie, designed to be recog-
nized as self by the feline immune system) that
neutralized feline NGF might have potential as a long-
acting analgesic in cats and potentially would have an
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improved safety profile compared to existing therapies.
In this study, we describe the properties of such a felin-
ized anti-NGF mAb in vitro and in vivo, including its
activity in alleviating signs of pain in a short-term, self-
resolving model of inflammation in cats.
Materials and Methods
Conversion of an Anti-NGF Antibody for Use in the
Cat
Monoclonal antibodies generated by immunization of rodents
are immunogenic if injected into other mammals. For use in
humans, rodent mAbs are modified for injection by a process
termed “humanizing” or “humanization”. By analogy, a rodent
mAb converted for treatment in the cat would be termed “felin-
ized”. To decrease the immunogenic potential of rat anti-mouse
NGF mAb aD119 in the cat, while retaining its high affinity for
NGF, amino acid substitutions were made to the heavy and light
chain variable domain framework sequences by alignment with a
collection of predicted protein sequences encoded by expressed
feline immunoglobulin (IgG) complementary deoxyribonucleic acid
(cDNA) sequences. This approach (that we refer to as PETization)
previously was used to generate a fully caninized anti-NGF mAb
that has a promising efficacy and safety profile in dogs.6–8 Where
an amino acid in the aD11 sequence corresponded to an amino
acid in the collection no change was made. Where it differed, the
most similar amino acid (eg, by charge or size) at that position in
the collection was substituted. If no similar amino acid was
Fig 1. NGF and anti-NGF antibody sequences. (A) Alignment of the mature peptide sequence of NGF from human, mouse, and cat.
Identical amino acids are indicated by dots and similar amino acids are underlined. (B) Variable heavy and (C) variable light chain
sequences of the anti-NGF antibody aD11 aligned to the felinized antibody NV-02. Identical amino acids are indicated by dots and similar
amino acids are underlined. Complementarity-determining regions (CDR) are boxed.
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available, the most abundant feline amino acid residue at that
position was chosen. The changes made are illustrated in Fig 1B
and C. Sixteen substitutions were made to the heavy chain variable
domain, of which 4 were conservative (ie, related by charge, size,
or hydrophobicity) and 22 substitutions were made to the light
chain variable domain, of which 10 were conservative. By this pro-
cess, the aD11 framework amino acid sequences were completely
felinized, with minimal changes made from the donor aD11 anti-
body. The felinized aD11 heavy chain variable domain sequence
was combined with an immunoglobulin heavy chain signal
sequence and the constant domain sequence of feline IgG heavy
chain isotype IgG1 to form the feN-HC1 sequence. The felinized
NV-02 light chain variable domain sequence was combined with a
light chain signal sequence and the constant domain sequence of
the feline kappa light chain to form the feN-kLC sequence. The
resulting amino acid sequences were converted to Chinese Hamster
Ovary (CHO) cell codon-optimized nucleotide sequences and
cloned separately into pcDNA3.1+ for expression in CHO cells.a
For small-scale work, antibodies (NV-02, NV-01 and caN-HCB-
kLC1) were transiently expressed in CHO cellsa and purified by
protein A chromatography from transfected CHO cell super-
natant. For larger scale in vivo experiments requiring more mate-
rial, NV-02 antibody was stably expressed in CHO cells.b Stable
CHO cell lines with high productivity were prepared with cDNA
encoding NV-02 heavy and light chains, and were cultured in a
fed batch system, before harvesting of supernatant containing
NV-02. The protein was purified by MabSelectSuRec and Sarto-
bind Qd chromatography, then concentrated and formulated into
phosphate-buffered saline (PBS) pH 7.2. Endotoxin concentrations
were determined using an Endosafe-PTSTM kit.
In Vitro Characterization of the Felinized Anti-NGF
Antibody
Complement C1q binding was assayed as previously
described.10 Plates were coated with 2.5 lg/mL mouse NGF and
blocked with 5% bovine serum albumin (BSA)/phosphate-buffered
saline (PBS). Coated wells were incubated for 1 hour at room tem-
perature with NV-02 antibody, or as a positive control a caninized
anti-NGF mAb with a IgG-B isotype (complement-binding) heavy
chain,6 diluted in PBS/1% BSA. Antibody concentrations ranged
from 10 lg/mL to 1.0 lg/mL. The plates were washed and incu-
bated for 1 hour at room temperature with human serum or heat-
inactivated human serum diluted 1/100 in veronal-buffered saline
containing 0.05% Tween-20, 0.1% gelatine, and 0.5% BSA. After
washing, plates were incubated with a 1/800 dilution of sheep anti-
human C1q-HRPe in PBS/1% BSA. After washing, plates were
developed by the addition of tetramethylbenzidine (TMB) sub-
strate.f Development was stopped by the addition of 2M H2SO4
and absorbance read at 450 nm. The absorbance at 450 nm
obtained using heat-inactivated serum was used as background
and subtracted from the absorbance at 450 nm obtained using
untreated serum.
The binding affinity of NV-02 to mouse NGF was analyzed by
surface plasmon resonance assay (SPR) using a ProteOn XPR36
SPRi biosensor equipped with a GLM chipf. The chip was condi-
tioned with 0.5% sodium dodecyl sulfate (SDS), 50 mM NaOH,
and 100 mM HCl. After conditioning, the lanes were activated
using equal parts of 1-ethyl-3-(-3-demethylaminopropyl) carbodi-
imide and N-hydroxysulfosuccinimide amine coupling reagents.
The NGF protein was immobilized to the chip at a concentration
of 50 lg/mL in sodium acetate buffer (pH 4.5). After immobiliza-
tion all 3 channels were deactivated using ethanolamine. The NV-
02 was passed across the surface at 500 nM, 250 nM, 125 nM,
62.5 nM, and 31.25 nM. The binding was displayed as a spectro-
gram. Controls were subtracted to give specific binding.
A Langmuir curve fit model then was used to determine the speci-
fic affinity. Inhibition of NGF binding by NV-02 was assessed
using TF-1 cells as previously described.6 TF-1 cells were starved
for 24 hours, then cultured in 96-well plates in media supple-
mented with 1 ng/mL mouse NGF and increasing concentrations
of NV-02 or caninized anti-NGF mAb NV-01. The plates were
incubated for 48 hour at 37°C/5% CO2 before measuring prolifer-
ation using a CellTiter 96 Aqueous One Solution Cell Prolifera-
tion Assay.g The assay was performed in triplicate. A mouse
IgG2a mAbh was used as a negative control.
Pharmacokinetics and Safety of NV-02 In Vivo
Pharmacokinetic (PK) studies were conducted in a research
colony of cats at Charles River Laboratories (CRL), Ireland,
after institutional ethics review panel approval (code CRL/001-
15/001). Purified NV-02 was injected SC, at 2.0 mg/kg, 5.6 mg/kg,
16.8 mg/kg, or 28 mg/kg into 8 cats (n = 2 animals/group) and
plasma samples were taken over the next 42 days. The concen-
tration of NV-02 in the plasma samples was determined using a
quantitative NGF-binding ELISA. Immunoassay plates (F96
Maxisorpi ) were coated with 100 lL of 0.1 lg/mL mouse NGF
in PBS and blocked with PBS/0.05% Tween 20/1% BSA. Assay
diluent was prepared by diluting pooled normal cat plasma in
PBS/0.05% Tween 20/1% BSA. Standards were prepared by
diluting NV-02 in assay diluent to 40, 30, 20, 10, 5, 2, and
1 ng/mL. Quality control (QC) samples were prepared from
independent stock solutions of NV-02 by diluting in assay dilu-
ent to final concentrations of 30, 15, and 3 ng/mL. Two individ-
ual dilutions were prepared for each QC level. Samples were
diluted to the required dilution in PBS/0.05% Tween 20/1%
BSA.
The NGF-coated wells were incubated for 1 hour at room tem-
perature with standard curve, QC and plasma samples. After
washing with PBS/0.05% Tween 20, the plates were incubated
with a 1/10,000 dilution of goat anti-feline IgG (heavy and light
chain specific)-horseradish peroxidase conjugate j in PBS/0.05%
Tween 20/1% BSA for 1 hour. Plates were washed and developed
by the addition of TMB substratei. Development was stopped by
the addition of 2M H2SO4. The assay was analyzed using a 4
parameter fit. An assay was considered to pass if 4 of 6 QC sam-
ples were within 20% of the expected concentration, including 1 of
each QC concentration. Plasma half-life was determined using the
program PK Solver (11).
Safety was assessed during the course of the study by the CRL
veterinarians, observing behavior (daily) and measuring weight
(daily), clinical chemistry variables (days 14 and 42: glucose, cre-
atine phosphokinase, sodium, chloride, potassium, phosphate,
cholesterol, creatinine, total protein, albumin, globulin, calcium),
and hematology assessments (days 0, 14, and 42: red blood cells,
hemoglobin, hematocrit, mean corpuscular volume, mean corpus-
cular hemoglobin, mean corpuscular hemoglobin concentration,
white blood cells, lymphocytes, monocytes, neutrophils, eosino-
phils, basophils, large unstained cells).
Model of Inflammatory Pain
A validated, reversible, and ethical model of inflammatory pain
in the cat induced by injection of kaolin into the footpad11 was
used, after institutional ethics review and approval at CRL, Ire-
land (CRL/001-14/004). After kaolin injection into the footpad, a
pain-induced lameness develops in that leg within 24 hour that
progressively recovers over a period of 7–14 days. Cats were then
returned to the colony. After review and approval by the CRL
institutional ethics committee, the kaolin model was used to assess
the analgesic potential of a single 2 mg/kg dose of NV-02-
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delivered SC. Vehicle (PBS) was administered SC as a negative
control. To maintain blinding, the administration of NV-02 or
vehicle was performed by investigators different from those who
assessed lameness. The investigators involved in the lameness
assessments were masked to the treatments administered to
decrease bias. The investigators involved in the administration of
NV-02 or vehicle control were not masked.
Thirty cats were used and allocated to 2 treatment groups
(n = 15 per group). Animals assigned to Group 1 served as a nega-
tive control group and were treated with PBS administered by SC
injection in the neck region. Animals assigned to Group 2 were
treated with NV-02 administered by SC injection at a dosage of
2.0 mg/kg. To facilitate peak plasma concentrations of NV-02
(based on PK data, Fig 4) and optimal distribution to the footpad,
NV-02 was given 4 days before a kaolin injection. On the day of
kaolin administration to the cats, general anesthesia was induced
using ketamine (approximately 7.5 mg/kg [0.075 mL/kg]) and
medetomidine (approximately 0.08 mg/kg [0.08 mL/kg]) by IM
injection. After kaolin injection, any cat that had not fully
recovered after 45 minutes of sedation was given atipamezole
hydrochloride (0.2 mg/kg [0.04 mL/kg]) IM to reverse the seda-
tion. One cat did not recover from the sedation and this event was
attributed to anesthetic death. The cats underwent experimental
induction of paw inflammation using 5.4 mL of 250 mg/mL kao-
link /PBS solution injected SC in portions at 6 sites in the right
hind paw. The degree of lameness induced by kaolin was scored
according to 4 levels using a discontinuous scoring system,6,11
where a score of 0 = full weight bearing; 1 = slightly lame (not
fully weight bearing but walking well); 2 = moderately lame
(slightly weight bearing and not walking well); and 3 = severely
lame (not weight bearing). All animals used in the study became
lame 24 hour after kaolin administration. Lameness assessments
were performed at the following times: before kaolin administra-
tion, pretreatment on study day 0; and at the following times after
dosing: 6h, +1d, +2d, +3d, +4d, +5d, +6d, and +7d. The lameness
scores were unblinded and scores from NV-02-treated cats were
compared to the placebo control-treated cats as described previ-
ously.6 Circumference measurements of the kaolin-injected paw
and rectal temperature measurement were taken daily and aver-
aged across each group.
Statistical Methods (in vivo kaolin experiment)
Descriptive statistics (number of subjects, mean, standard devia-
tion, standard error of the mean, minimum, median, and maxi-
mum values) were determined. Repeated measures analysis of
variance (ANOVA) methods were employed. The model included
study day as a fixed effect and animal identification as a random
effect. Assumptions of normality of residuals were investigated
using the Shapiro-Wilk test. If the P value was < .05 then it was
determined that the distribution cannot be approximated by a nor-
mal curve. The values then were ranked in ascending order with
tied values given a mean rank before running statistical models.
The covariance structure that provided the smallest Akaike’s infor-
mation criterion (AIC) was selected. Pairwise comparison of the
active dose to placebo was generated from the repeated measures
ANOVA model.
Results
Characterization of Felinized Anti-NGF mAb In Vitro
The felinized anti-NGF mAb NV-02 heavy and light
chain cDNA sequences were subcloned into a mam-
malian expression vector and transfected into CHO
cells. Purified NV-02 mAb was isolated from transfected
CHO cell supernatants (previously cultured in animal
component-free chemically defined media) by Protein A
affinity chromatography, ion-exchange chromatography,
and sterile filtration. This procedure resulted in highly
purified preparations of NV-02 (99.3% monomer by
size-exclusion high-performance liquid chromatography
with low endotoxin concentrations (<0.1 EU/mg).
Purified NV-02 mAb was assayed by size-exclusion
fast protein liquid chromatography (FPLC) and shown
to consist predominantly of a monomeric species with
an apparent molecular weight of approximately 150 kDa
(Fig 2A), which was confirmed by non-reducing sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Analysis by reducing SDS-PAGE identified
heavy and light chains of approximately 50 kDa
and 25 kDa, respectively, as expected (Fig 2B). Unex-
pected heterogeneity of the light chains was assessed by
N-glycanase treatment of NV-02 that resulted in a
Fig 2. Characterization of purified felinized anti-NGF antibody
NV-02. (A) Size-exclusion chromatography of purified NV-02.
(B) SDS-PAGE of nonreduced (NR) and reduced (R) NV-02.
Corresponding molecular weight standards are identified (numbers
in kDa). (C) Glycosylation analysis of NV-02. NV-02 (nGlyc )
was treated with N-Glycanase (nGlyc +) and analyzed by reducing
SDS-PAGE. The arrow indicates the position of glycosylated light
chain variants that are absent after treatment. (D) Comparison of
the translated cDNA and genomic DNA-derived protein sequences
of the C-terminal region of the cat kappa light chain showing the
presence of a glycosylation site (boxed, NxS) not found in the
kappa light chain of mouse or human IgG.
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decrease in the apparent molecular weight of both the
heavy and light chains (Fig 2C). Analysis of genomic
and expressed cDNA feline kappa light chain sequences
identified an N-linked glycosylation site close to the
C-terminus (Fig 2D) that likely explains the heterogene-
ity, with some light chains more modified than others.
Analysis by mass spectrometry confirmed the presence
of a heterogeneous population of glycans on the light
chains seen with SDS-PAGE (Fig 2C; not shown).
Purified NV-02 mAb was tested for its ability to neu-
tralize NGF in vitro using an NGF-dependent prolifera-
tion assay of TF-1 cells, as previously described.6 The
NV-02 had equivalent potency in this assay as caninized
anti-NGF mAb NV-01 (Fig 3A). Surface plasmon reso-
nance (SPR) assays (Fig 3B) indicated high-affinity bind-
ing of NV-02 to NGF (KD = 20 pM), equivalent to
NV-01,6 with no appreciable dissociation of ligand after
switching the flow to buffer, indicating that the high
affinity of binding was caused by a very slow off rate.
Using an ELISA for detection of C1q, the first compo-
nent of the complement cascade, NGF-captured NV-02,
was shown to bind little or no C1q (Fig 3C) by compar-
ison with a C1q-binding control antibody (caN-HCB-
kLC1).6 This result suggests that NV-02 will not initiate
complement-mediated immune damage, an important
safety consideration before its use in vivo.
Pharmacokinetics and Safety of NV-02 In Vivo
The concentration-time plots of NV-02 in the feline
plasma samples are depicted in Fig 4. The PK profiles
are typical of IgG injected to other mammals, with an
absorption phase from the site of injection to plasma
followed by a decay phase corresponding to elimination
from the plasma. After absorption from the injection
site, peak plasma concentrations (Cmax) were achieved
at approximately 3 days (Tmax; range, 1.9–4.3 days).
The averaged elimination phase half-life was calculated
to be 9 days (range, 7–15 days).
There were no changes in body weights, clinical
chemistry measurements, and hematology assessments
in any of the cats. No adverse reactions or behavioral
changes were noted by the veterinarians.
Effect of NV-02 administration in a Kaolin-induced
Model of Inflammatory Lameness
Lameness scores were ranked before generating the
repeated measures ANOVA because it was determined
that the distribution could not be approximated by a
normal curve. The covariance structure that provided
the smallest AIC was heterogeneous autoregressive.
Pairwise comparisons to placebo yielded statistically sig-
nificant lower lameness scores in the NV-02 group at
day 2 (P = .0027), day 3 (P = .0166), day 4 (P = .0063),
day 5 (P = .0085), day 6 (P = .0014), and day 7
(P = .0034). Mean lameness scores are presented in
Fig 5. No difference was observed in mean rectal tem-
perature or mean paw circumference measurements
between placebo- and NV-02-treated cats on any treat-
ment day (data not shown).
Discussion
Our study represents the initial characterization of a
therapeutic antibody with the potential to treat acute
and possibly chronic pain in cats. No pharmaceutical or
Fig 3. Functional characterization of the felinized anti-NGF anti-
body NV-02. (A) Inhibition of NGF induced proliferation of TF-1
cells in vitro. 1 ng/mL NGF was incubated with NV-02 (●), a
caninized anti-NGF mAb (NV-01, ▲) or an irrelevant IgG control
antibody (□) at concentrations ranging from 10 to 0.01 ng/mL.
(B) Binding of NV-02 to immobilized NGF assessed by surface
plasmon resonance (SPR). Various concentrations of NV-02
(500 nM, 250 nM, 125 nM, 62.5 nM, and 31.25 nM) were passed
over NGF for 60 second then the flow switched to buffer. Relative
binding is plotted as response units (RU) over time. (C) Comple-
ment C1q binding ELISA. NV-02 (□) or a control non-C1q bind-
ing caninized anti-NGF mAb, caN-HCB2-kLC1 (●) were bound
to immobilized NGF and incubated with serum. C1q binding was
detected by polyclonal anti-C1q-HRP.
Felinized Anti-NGF mAb in Cats 1133
biopharmaceutical products are approved by the United
States Food and Drug Administration (US-FDA) for
long-term control of chronic pain in cats, unlike in
dogs, where several NSAIDs are FDA-approved for
this indication. This situation exists although chronic
pain associated with degenerative joint disease appears
to be very prevalent in cats.13,14 Two NSAIDs, meloxi-
cam and robenacoxib, are FDA-approved for the treat-
ment of postoperative pain in cats, but meloxicam is
restricted to a single administration and robenacoxib to
a maximum of 3 days. In Europe, meloxicam is
approved for unlimited daily use in the cat for the con-
trol of musculoskeletal pain, yet the same drug (meloxi-
cam) carries a boxed warning in the United States,
which reads, “Repeated use of meloxicam in cats has
been associated with acute renal failure and death. Do
not administer additional injectable or oral meloxicam
to cats”. The controversy over repeated administration
of meloxicam, or indeed any NSAID, aside, clearly the
need for new analgesic medications for the control of
chronic pain in cats is high.
Nerve growth factor is a highly conserved dimeric
peptide hormone produced by proteolytic cleavage of a
pre-pro-peptide precursor. During development, NGF is
a neurotrophic factor essential for the survival of sen-
sory and sympathetic neurons.15,16 In the adult, NGF is
expressed at sites of injury and inflammation and is a
major factor promoting pain and hyperalgesia.4,5 Nerve
growth factor acts on 2 receptors, the high-affinity trkA
receptor and low-affinity p75 receptor. The modulating
effect of NGF on nociceptive neurons is mediated by
the trkA receptor, resulting in increased immediate and
long-term excitability3 by modulation of ion channels
such as the transient receptor potential vanilloid recep-
tor (TRPV1).3 Nerve growth factor also causes sprout-
ing of nerve endings into the site of inflammation2 and
has been detected in neuromas.17 Administration of
NGF can potentiate pain, and mutations in the trkA
receptor are associated with diminished pain responses.4
Furthermore, antibodies that neutralize NGF are highly
effective analgesics in animal models of inflammatory
pain, arthritis, cancer pain, and bone fracture.2,3
This encouraging biological activity has resulted in sev-
eral NGF antagonists being developed for the treatment
of pain in humans.3 The clinical efficacy of anti-human
NGF mAbs has been demonstrated in several pain states
(eg, OA, lower back pain, cystitis) in clinical trials,
including large Phase 3 studies.3–5,18,19 The NGF inhibi-
tory antibodies were generally very well tolerated (consis-
tent with a benign profile in 6-month primate studies20)
and mild to moderate, transient peripheral sensation
changes were the only neurological consequences.3–5 In
2010, the FDA instructed several companies to put their
clinical programs on hold (except those for cancer pain)
after observations of worsening of clinical signs in a small
proportion of patients with OA, requiring accelerated
joint replacement.21 The cause of this worsening, termed
“rapidly progressing OA”, was debated, although in
some patients, the accelerated OA appeared to be associ-
ated with concomitant NSAID use. Nonetheless, the
FDA expert review panel overseeing these studies recom-
mended that the clinical halt be lifted in 2012.22
The first veterinary application of an anti-NGF mAb
recently was described in the form of a fully caninized
anti-NGF mAb.6 This high-affinity mAb (NV-01) also
Fig 4. Pharmacokinetic profile of NV-02 in cat plasma following subcutaneous administration at various dose levels. A single dose of
NV-02 at 2 mg/kg and 5.6 mg/kg (A) or 16.8 mg/kg and 28 mg/kg (B) was administered to two cats per dose level and the plasma concen-
tration of NV-02 was assayed at the times indicated by a quantitative NGF-binding ELISA.
Fig 5. Lameness assessment scores following subcutaneous injec-
tion of NV-02 to cats. Cats were injected with vehicle (black bars;
N = 15) or 2 mg/kg NV-02 (grey bars; N = 14) on Day-4. Kaolin
was administered on Day 0 and lameness was assessed over the
following 7 days using a visual analog scoring system. Average
lameness scores are presented for each group with error bars
representing SEM. Significant P values generated by repeated mea-
sures ANOVA are denoted *P < .05 and **P < .01 and indicated
above each pair.
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was derived from aD119 and is a potent inhibitor of
NGF in vitro. In dogs, the mAb had a long serum half-
life, did not generate neutralizing anti-drug antibodies
and was effective in decreasing signs of lameness caused
by inflammation. In a pilot clinical study of 9 dogs, a
single dose of NV-01 mAb was well tolerated and sig-
nificantly decreased clinical signs of pain and improved
mobility in OA dogs, as assessed by owners using the
Canine Brief Pain Inventory.7 The magnitude of
improvement in clinical signs was similar to that seen
previously with NSAIDs and the duration of effect was
at least 4 weeks. More recently, in a blinded, placebo-
controlled study of 26 dogs with degenerative joint dis-
ease (including OA), a single dose of NV-01 similarly
was well tolerated and effective at decreasing pain and
improving mobility.8 The NV-01-treated dogs showed
improvement in 3 independent clinical scoring methods,
again in magnitude similar to that observed with
NSAIDs and over a period of 4 weeks. Furthermore,
the NV-01-treated dogs were more active during the
daytime, as assessed by collar-mounted accelerometers.
Given its role in mediating inflammatory pain in
rodents, dogs, and humans, we reasoned that NGF
would be a useful therapeutic target in cats with painful
conditions. Feline NGF and its receptor are closely
homologous to those of other species. For mature
(beta) NGF, there is 100% identity between dog and
cat, 91% identity between human and cat, 85% identity
between rat and cat, and 82% identity between mouse
and cat. Nerve growth factor and its receptor trkA are
expressed in similar tissues in cats and humans, appear
to be under similar control mechanisms, and have simi-
lar functions.23,24 As with other mammals, the feline
immune system shares major immunoglobulin types,
including IgG, IgG-Fc receptors including the high-affi-
nity FcR, and the neonatal FcRn, which potentiates
IgG half-life in vivo.25–27
Felinized anti-NGF mAb NV-02, like the caninized
mAb NV-01 previously described, retains the high
affinity of its parent mAb aD11 (Fig 3B) and has
similar ability to neutralize NGF in vitro (Fig 3A),
suggesting that NV-02 retains the structural integrity
of the parent mAb. Because the concentration of anti-
body required to neutralize a given amount of NGF
is decreased with increased affinity and potency, the
results with NV-02 are predictive of low dosage for
in vivo efficacy. Furthermore, NV-02 does not recruit
complement (Fig 3C), which is important for its safe
use in vivo.
We observed no safety signals in cats injected with a
single dose of NV-02 by the SC route at dosages up to
28 mg/kg. Although the safety studies of this small
cohort were limited to observations of behavior, weight
change, blood chemistry, and hematology, we conclude
that NV-02 lacks overt toxicity. Further research will be
necessary to confirm this safety profile. Delivery of anti-
NGF mAbs SC limits their exposure to the periphery,
because mAbs do not cross the blood-brain barrier
(BBB). Consequently, action on the central nervous sys-
tem is avoided. Anti-NGF mAbs from the maternal cir-
culation (via the placenta and developing BBB) cause
fetal abnormalities in rodents,28,29 and in pregnant non-
human primates, caused increased stillbirth, postbirth
infant mortality and morbidity, decreased infant growth,
sensory and sympathetic nervous system changes, and
decreased infant primary antibody responses.30 The use
of anti-NGF mAbs should be avoided in pregnant or
lactating animals. By contrast, in the adult, very high
doses of anti-NGF mAb delivered IV or SC were well
tolerated and extensive analysis identified no effects on
adult peripheral nerves.31
When administered to cats SC, 4 days before kaolin,
NV-02 decreased the severity of lameness and main-
tained protection from lameness over the following
week. As previously observed for anti-NGF mAbs in
other species,2 NV-02 did not decrease inflammatory
pyrexia or swelling of the paw compared with placebo-
treated cats. A similar duration of effect was observed
previously with a caninized anti-NGF mAb in the kao-
lin model in dogs, and longer effects were observed in
dogs with degenerative joint disease (DJD). Studies of
cats with DJD will be necessary to determine whether
NV-02 is effective in providing analgesia in this setting,
as well as whether a duration of effect >7 days can be
achieved after a single injection.
Monoclonal antibodies have become an important
part of the therapeutic treatment options for several dis-
eases of humans including inflammation, autoimmunity,
cancer, allergy, and blindness because of their combina-
tion of efficacy, duration of effect, and safety. The
PETization approach, described here with the anti-
NGF mAb for cats (NV-02) and previously with dogs
(NV-01) produces mAbs with similar properties to
humanized mAbs and potentially will allow the use of
mAbs for the treatment of many diseases in veterinary
patients.
Conclusions
Our data support the hypothesis that neutralization
of NGF in cats with the mAb NV-02 may have the
potential to provide appropriately safe analgesia in the
cat, potentially for prolonged durations. These conclu-
sions are based on our findings of high affinity for and
potent inhibition of NGF in vitro, no evidence of bind-
ing complement component C1q, a long plasma half-
life, and a lack of observed toxicity in vivo.
Further work will be necessary to assess: (1) the value
of this mAb in treating chronic pain states in the cat,
such as the pain associated with degenerative joint dis-
ease; (2) the optimal route of delivery, dose, and dosing
strategy for best efficacy; and (3) its safety in larger
cohorts of normal or diseased cats.
The mAb NV-02 has the potential to provide an
advance in the treatment of many cats with joint pain
associated with OA and other forms of DJD. While
this paper was under review, a paper describing the
safety and efficacy of NV-02 mAb in cats with degen-
erative joint disease has been published in JVIM
(Gruen et al. 2016). USAN have adopted the non-
proprietary name frunevetmab for anti-NGF mAb
NV-02.
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